United Therapeutics Corporation $UTHR Shares Bought by Erste Asset Management GmbH

Erste Asset Management GmbH lifted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 13.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,011 shares of the biotechnology company’s stock after purchasing an additional 5,223 shares during the period. Erste Asset Management GmbH’s holdings in United Therapeutics were worth $21,512,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in UTHR. Clearstead Advisors LLC raised its holdings in shares of United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares during the period. Independent Advisor Alliance raised its holdings in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the period. Bessemer Group Inc. raised its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 28 shares during the period. Florida Financial Advisors LLC raised its holdings in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 28 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 35 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 624,043 shares of company stock worth $351,930,785 over the last quarter. Insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Royal Bank Of Canada reduced their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Stock Performance

Shares of UTHR opened at $544.69 on Tuesday. The company’s 50 day moving average price is $568.47 and its 200 day moving average price is $519.64. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The company has a market capitalization of $23.12 billion, a PE ratio of 20.11, a PEG ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the firm posted $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.